Drugs News and Research RSS Feed - Drugs News and Research

Antibodies may trigger psychiatric illness in children

Antibodies may trigger psychiatric illness in children

A world first study revealing the presence of two antibodies in a sub-group of children experiencing their first episode of psychosis affirms a longstanding recognition that auto-immune disorders play a significant role in psychiatric illness. [More]
New osteoporosis drug may also be useful for treating brittle bone disease

New osteoporosis drug may also be useful for treating brittle bone disease

New research at the University of Michigan offers evidence that a drug being developed to treat osteoporosis may also be useful for treating osteogenesis imperfecta or brittle bone disease, a rare but potentially debilitating bone disorder that that is present from birth. [More]
Mylan announces U.S. launch of Amlodipine and Valsartan Tablets

Mylan announces U.S. launch of Amlodipine and Valsartan Tablets

Mylan N.V. today announced the U.S. launch of Amlodipine and Valsartan Tablets, 5 mg/160 mg, 5 mg/320 mg, 10 mg/160 mg, 10 mg/320 mg, which is the generic version of Novartis' Exforge Tablets. [More]
PAREXEL introduces new version of Regulatory Information Management platform

PAREXEL introduces new version of Regulatory Information Management platform

PAREXEL International Corporation, a leading global biopharmaceutical services provider, today introduced the latest version of its Regulatory Information Management (RIM) platform: LIQUENT InSight 6.0. [More]
Study provides new estimates of opioid misuse, addiction

Study provides new estimates of opioid misuse, addiction

New estimates suggest that 20 to 30 percent of opioid analgesic drugs prescribed for chronic pain are misused, while the rate of opioid addiction is approximately 10 percent, reports a study in the April issue of PAIN, the official journal of the International Association for the Study of Pain. [More]
New analysis raises questions about common use of antidepressant drugs for anxiety disorders

New analysis raises questions about common use of antidepressant drugs for anxiety disorders

A new analysis reported in JAMA Psychiatry raises serious questions about the increasingly common use of second-generation antidepressant drugs to treat anxiety disorders. [More]
China Pharma's revenue decreases 24% to $24.9 million in fiscal year 2014

China Pharma's revenue decreases 24% to $24.9 million in fiscal year 2014

China Pharma Holdings, Inc., an NYSE MKT listed corporation with its fully-integrated specialty pharmaceuticals subsidiary based in China, today announced financial results for the year ended December 31, 2014. [More]
New HCV therapies cost-effective in specific groups of HCV-infected patients

New HCV therapies cost-effective in specific groups of HCV-infected patients

A study led by Boston Medical Center researchers demonstrates that while new therapies to treat Hepatitis C Virus (HCV) are highly effective, they are cost-effective and provide the greatest value in specific groups of HCV-infected patients. [More]
Less-toxic drug combined with fasting may kill cancer cells

Less-toxic drug combined with fasting may kill cancer cells

Fasting in combination with chemotherapy has already been shown to kill cancer cells, but a pair of new studies in mice suggests that a less-toxic class of drugs combined with fasting may kill breast, colorectal and lung cancer cells equally well. [More]
Useful tips for physicians to help patients make the right choice on statin drugs

Useful tips for physicians to help patients make the right choice on statin drugs

Cholesterol-lowering statins have transformed the treatment of heart disease. But while the decision to use the drugs in patients with a history of heart attacks and strokes is mostly clear-cut, that choice can be a far trickier proposition for the tens of millions of Americans with high cholesterol but no overt disease. [More]
Allen Institute for Brain Science leads international effort to advance analysis of single neurons

Allen Institute for Brain Science leads international effort to advance analysis of single neurons

The Allen Institute for Brain Science is spearheading a landmark international effort to define and advance the state-of-the-art digital reconstruction and analysis of single neurons. The project launching today, called BigNeuron, aims to create reliable high-throughput and quantitative 3D reconstructions of the thousands of branches that make up individual neurons: a crucial step to ultimately understanding how the brain encodes information. [More]
Researchers identify potential drug molecule that kills cancer cells

Researchers identify potential drug molecule that kills cancer cells

The average living cell needs communication skills: It must transmit a constant stream of messages quickly and efficiently from its outer walls to the inner nucleus, where most of the day-to-day decisions are made. [More]
New oral drug shows promise in patients with chronic kidney disease

New oral drug shows promise in patients with chronic kidney disease

Patients with chronic kidney disease may be treated with a class of medications called Renin Angiotensin Aldosterone System inhibitors (RAASI's). Although these drugs protect the heart and kidney, a significant percentage of patients develop a dangerous side effect -- high potassium levels in the blood (hyperkalemia). [More]
New drug shows potential against rare type of acute leukemia

New drug shows potential against rare type of acute leukemia

Researchers at the University of Michigan Comprehensive Cancer Center have developed a new drug that shows potential in laboratory studies against a rare type of acute leukemia. And additional studies suggest the same compound could play a role in prostate cancer treatment as well. [More]
Cantrixil proves highly effective at killing human ovarian stem cells in pre-clinical study

Cantrixil proves highly effective at killing human ovarian stem cells in pre-clinical study

US-Australian drug discovery company, Novogen Ltd, and its subsidiary, CanTx, Inc., and Yale University, on March 27 released pre-clinical data on experimental anti-cancer drug, Cantrixil. The data was presented as an oral presentation by Professor Gil Mor MD PhD of Yale Medical School to the 62nd Annual Scientific Meeting of the Society of Reproductive Investigation in San Francisco, CA. [More]
Caris Life Sciences study may have potentially significant benefit in patients with uterine cancer

Caris Life Sciences study may have potentially significant benefit in patients with uterine cancer

Caris Life Sciences today announced the presentation of a study that found drugs targeting specific pathways may have potentially significant benefit in a select subset of patients with uterine cancer. The study results were highlighted today in an oral presentation in a Plenary Session at the Society of Gynecologic Oncology 2015 Annual Meeting on Women's Cancer in Chicago, Ill. [More]
Hospira announces availability of INFLECTRA (infliximab) in Canada

Hospira announces availability of INFLECTRA (infliximab) in Canada

Hospira, Inc., a global leader in biosimilars and the world's leading provider of injectable drugs and infusion technologies, announces the availability of INFLECTRA (infliximab) in Canada, the country's first subsequent entry biologic (SEB) monoclonal antibody (mAb) therapy. [More]
Amgen receives FDA priority review designation for Kyprolis to treat relapsed multiple myeloma

Amgen receives FDA priority review designation for Kyprolis to treat relapsed multiple myeloma

Amgen today announced that the U.S. Food and Drug Administration (FDA) has accepted the supplemental New Drug Application (sNDA) of Kyprolis® (carfilzomib) for Injection for the treatment of patients with relapsed multiple myeloma who have received at least one prior therapy. [More]
CRT, BioInvent, and University of Southampton partner to develop new immunotherapy treatments for cancer

CRT, BioInvent, and University of Southampton partner to develop new immunotherapy treatments for cancer

Cancer Research Technology, the commercialization and development arm of Cancer Research UK and BioInvent International today announce the start of a two-year research collaboration with leading antibody researchers at the University of Southampton. [More]
Columbia licenses exclusive worldwide rights to novel intra-vaginal ring technology

Columbia licenses exclusive worldwide rights to novel intra-vaginal ring technology

Columbia Laboratories, Inc., a specialty pharmaceutical company focused on the development of therapeutics for women's health, has licensed exclusive worldwide rights to a novel intra-vaginal ring technology for the delivery of one or more pharmaceuticals at different dosages and release rates in a single segmented ring. [More]
Advertisement
Advertisement